SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under pressure amid reports of a board investigation into CEO Jensen Huangs alleged affair with a woman suspected of ties to Chinese intelligence, with traders debating whether the controversy could threaten his leadership or involve export-control breaches; those allegations remain unproven. Some see the selloff as an overreaction and are buying the dip ahead of earnings, while others cite governance and China-related uncertainty as reasons to sell or wait.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is under pressure after its Q3 report and analyst target cuts sharpened concerns about satellite launch delays, a slower path to commercial service, and spending on its own rocket program. Bears question execution and cash needs, while bulls point to government and Japan-related funding and the companys longer-term deployment plans.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines quarterly revenue beat and raised sales outlook were overshadowed by narrowing gross margins and unchanged EBITDA guidance, sparking a sharp selloff as traders questioned whether growth is translating into profitability; debt concerns add to the bearish case. Some traders call the drop an overreaction to a strong quarter and are buying the dip, while others see the margin pressure as a more serious warning.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Goldman Sachs upgrade to Buy and a wave of analyst target increases are drawing attention, building on Zetas strong quarterly results and raised guidance. Traders are largely bullish on the breakout, though some remain wary of volatility and resistance after the earnings-related swings.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A disappointing Q3 reportan unexpected loss, weaker profitability guidance, margin pressure and a sequential subscriber declinehas driven HIMS sharply lower. Bearish traders question whether growth can translate into profits, while bulls see an oversold buying opportunity and point to the planned Peptides+ launch as a potential growth catalyst.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts AI data-center spending and reported pullbacks from some third-party cloud and expansion deals are driving debate over whether the company is tightening execution or signaling weaker AI demand. Bears point to heavy capex, financing needs and data-center delays as risks to cash flow, while bulls see the moves as a shift toward newer capacity and a more disciplined buildout.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins quarterly results and a new share-repurchase authorization are driving attention, with traders welcoming stronger profitability and margins. The reaction is tempered by concerns about declining same-store sales and frustration that solid results have not resolved the stocks persistent OTC valuation discount; a relisting remains speculative.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A quarterly earnings beat and stronger-than-expected outlook sparked a sharp rally, but shares gave back much of the gain after managements cautious tone. Traders are split between seeing a turnaround and potential short squeeze, and questioning whether growth is sustainable given weak underlying trends and the lack of recent buybacks.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,110,071. The last known price of Bitcoin is 74,895.40905656 USD and is down -0.28 over the last 24 hours. It is currently trading on 12776 active market(s) with $26,892,693,016.04 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins selloff is drawing attention as hotter-than-expected U.S. inflation strengthens fears of further Fed rate hikes, with traders also pointing to leveraged-position liquidations and broken technical support. The community is split between expecting more downside and viewing the pullback as a buying opportunity, with some looking for a bounce near key support levels.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

Claims that Anthropic released an AI alternative to Microsoft Office have reignited fears among traders that AI tools could disrupt software companies across IGV. The community is divided between warnings of a renewed SaaSpocalypse and views that the threat is overstated and AI can strengthen established software platforms.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles

Equity

BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock. 


Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth 

 Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.

First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund

Bearish Sentiment

<ul class="summary-bullets"><li>Seigerman highlighted two recent discontinuations for the individualized mRNA candidate autogene cevumeran — jointly developed by BioNTech and Genentech — in bladder cancer and colorectal cancer.</li><li>Evercore ISI called the PFS miss “disappointing, but consistent with our reading of the earlier Phase 2 data.”</li><li>Citi pointed out that the trial design still allows a positive outcome if OS improves, “preserving a meaningful development path.”</li></ul> BioNTech shares (BNTX) closed down roughly 7% on Tuesday after the company reported that its investigational mRNA cancer immunotherapy BNT113 failed to show a statistically significant progression-free survival (PFS) benefit in a key late-stage trial, a result an analyst said reflects a broader pattern of challenges for mRNA cancer vaccines.In the Phase 2/3 AHEAD-MERIT study, BNT113—an off-the-shelf mRNA immunotherapy —was tested in combination with Merck’s drug pembrolizumab versus pembrolizumab alone as first-line treatment for certain patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma.At the first analysis of the dual primary endpoints, the combination did not show a statistically significant PFS improvement, the company said on Tuesday. The independent data monitoring committee recommended that the trial continue as planned to assess overall survival, the second primary endpoint. Under the pre-specified trial design, a significant OS benefit would still constitute a positive outcome even without a PFS win.<h2 class="st-heading-2">BNTX Analyst Reactions Highlight Reduced Confidence</h2>BMO Capital Markets analyst Evan David Seigerman said that the PFS miss “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock.Seigerman, who maintains a Market Perform rating and $105 price target, said the miss on progression-free survival (PFS)—the length of time patients lived without their cancer getting worse—for BNT113 plus pembrolizumab in the AHEAD-MERIT study leaves open the possibility of a later overall survival (OS) benefit, meaning patients living longer overall, but with significantly reduced confidence.He highlighted two recent discontinuations for the individualized mRNA candidate autogene cevumeran — jointly developed by BioNTech and Genentech — in bladder cancer and colorectal cancer. While an OS improvement is still possible, BMO views it as less likely given today’s miss.Evercore ISI and Citi called the PFS miss disappointing. Evercore, which rates the shares ‘Outperform’ with a $130 target, said BioNTech’s valuation is tied more closely to the outlook for its pumitamig program and rival Summit Therapeutics’ upcoming readout for its experimental drug ivonescimab in first-line metastatic non-small-cell lung cancer than to this single result.Citi kept a ‘Buy’ rating and $125 target, and pointed out that the trial design still allows a positive outcome if OS improves, “preserving a meaningful development path.”<h2 class="st-heading-2">BioNTech's Optimistic Stance</h2>BioNTech Chief Medical Officer Özlem Türeci stated on Tuesday that while the PFS result was not statistically significant, the data support continued evaluation and indicate the candidate is engaging its intended mechanism. She emphasized that immune-mediated anti-tumor effects can build over time, making the OS analysis critical for assessing durable benefit in this HPV-driven disease, for which no approved HPV-targeted therapies currently exist.Investors will now watch for OS data from AHEAD-MERIT, expected later, as the company continues to position mRNA immunotherapies as a core pillar of its oncology strategy amid the transition away from COVID-19 vaccine revenues.<h2 class="st-heading-2">How Did BNTX Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$BNTX" data-symbol-id="BNTX" href="https://stocktwits.com/symbol/BNTX" target="_blank">BNTX stock</a> jumped from neutral to bullish territory over the past 24 hours, while message volume stayed at normal levels.A Stocktwits user opined that the stock will slip further, noting that the company’s CEO Uğur Şahin, as well as CMO Özlem Türeci, who also co-founded the company, are slated to step down by the end of the year, leaving the company without fresh leadership for a while.<stembedurl>https://stocktwits.com/IndyOne/message/666392163</stembedurl>Another user opined that the trial outcome was expected given the difficulty of treating late-stage cancer and voiced optimism for the company’s other oncology assets.<stembedurl>https://stocktwits.com/eightytwentie/message/666385168</stembedurl>BNTX stock has fallen by about 7% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gme-rises-after-hours-as-ryan-cohen-buys-another-844-k-shares-worth-near-23-m/cZxBuMNRBYp">GME Rises After Hours As Ryan Cohen Buys Another 844K Shares Worth Near $23M</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Keenjee Nama, senior research nurse, holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell lung cancer (NSCLC) at the University College London Hospital clinical research facility, Picture date: August 20, 2024. (Photo by Aaron Chown/PA Images via Getty Images)

BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock. 

BioNTech SE - ADR

First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

iShares Biotechnology ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

FBT First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Fundamentals

Latest FBT News